Liven Pharma Marks First Export to Arab Region, Eyes Expansion

Liven Pharma Marks First Export to Arab Region, Eyes Expansion

Liven Pharma Limited has officially entered the Arab pharmaceutical market with its first successful export order, signaling a major milestone in the company’s growth strategy. The announcement was made via a notice to the Pakistan Stock Exchange (PSX), confirming that the order—received last year—was fulfilled this year.

Strengthening Financial Position

To support its expansion and reinforce its financial standing, Liven Pharma recently unveiled plans to raise Rs200 million through a rights issue. The company will issue 20 million ordinary shares at Rs10 per share, representing approximately 21.5% of its current paid-up capital. This translates to 21.496 rights shares for every 100 ordinary shares held by shareholders at the close of the share transfer books.

A Legacy of Pharmaceutical Excellence

Founded in 1991 and converted into a public limited company in 1992, Liven Pharma has built its reputation on manufacturing high-quality pharmaceuticals and allied products. The company’s latest move into the Arab region reflects its commitment to expanding its footprint and tapping into new international markets.

Looking Ahead

With its first export completed and fresh capital on the horizon, Liven Pharma is poised for further growth. The company’s strategic initiatives aim to strengthen its position in the regional pharmaceutical landscape and attract new investment opportunities.